Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
$68.16
$1.48(2.88%)
At close: 4:00 PM EST
$68.16
$1.48(2.88%)
Day’s Range― - ―
52-Week Range$46.26 - $79.50
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.35M
Market Cap
$7.92B
Enterprise Value$9.78B
Total Cash (Recent Filing)$701.96M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)14.3
Beta0.41
Next Earnings
Feb 24, 2026EPS Estimate
1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.72
Shares Outstanding117,597,000
10 Day Avg. Volume2,746,740
30 Day Avg. Volume2,353,525
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)16.67
Price to Sales (P/S)5.97
P/FCF Ratio12.95
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue7.87
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda11.03
Forecast
1Y Price Target
$77.63Price Target Upside13.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement raised FY25 guidance for the fourth time—now calling for $1.30-1.38B total revenue and $850-880M in royalties—and reiterated expectations for continued sequential royalty growth in 4Q25.
Regulatory ApprovalsThe launch of Rybrevant FASPRO provides more reasons for confidence in continued growth momentum.
Technology And InnovationHalozyme’s recombinant hyaluronidase enzyme (ENHANZE) is the gold standard for subcutaneous drug development.
Bears Say
Acquisition ConcernsQuestions remain regarding the risk profile for Halozyme's proposed Elektrofi acquisition.
Clinical Data UncertaintyFailure to generate favorable clinical data from ongoing programs poses a risk.
Commercial RisksRisks include commercial risk with ENHANZE, especially in the rapidly evolving multiple myeloma indication, and partnership risk with respect to Janssen.
Halozyme News
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $46.26 and its highest was $79.50 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $7.92B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 24, 2026 which is in 63 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Nov 03, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 1.9.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 117,597,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.72 in its last earnings report, beating expectations of $1.63. Following the earnings report the stock price went up 2.795%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.63 (13.89% Upside)
$77.63 (13.89% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 83%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 603.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.32%
12-Months-Change
Fundamentals
Return on Equity
124.50%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. (HALO) is a biotechnology company specializing in the development and commercialization of novel therapeutics for patients with unmet medical needs. The company focuses primarily on drug delivery solutions and the development of enzymatic therapies that facilitate the subcutaneous delivery of biologics. Halozyme’s core product, Hylenex, is an injectable formulation of hyaluronidase that enhances the absorption and dispersion of other injected drugs, making it a valuable tool in various therapeutic areas including oncology and diabetes.
HALO Company Deck
HALO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call revealed strong financial performance driven by robust revenue growth from key subcutaneous therapies and strategic acquisitions. However, there are some challenges with collaboration revenue declines and pending acquisitions. Overall, the positive aspects significantly outweigh the negatives.View all HALO earnings summariesHALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
$77.63
▲(13.89% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Bio-Techne
―
Moderna
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---